Zolmitriptan
| Evidence Level: L5 | Predicted Indications: 2 |
Table of Contents
Zolmitriptan: Atrophoderma vermiculata
One-Sentence Summary
Zolmitriptan is a triptan (5-HT1B/1D receptor agonist) originally used for the acute treatment of migraine. The TxGNN model predicts it may be effective for atrophoderma vermiculata, but there are currently no registered clinical trials and 18 publications, which are mostly general migraine reviews rather than studies of this specific subtype.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Atrophoderma vermiculata |
| TxGNN Prediction Score | 0.9990 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 15 of 16; dormant: 1) |
| Number of DINs | 16 (marketed: 15) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Zolmitriptan is a selective 5-HT1B/1D receptor agonist that acts both centrally and peripherally. Preclinical work suggests it inhibits trigeminovascular activation in the brain as well as in the periphery. This is the basis for its use in acute migraine attacks, where it relieves headache and associated symptoms such as nausea, photophobia and phonophobia.
The very high TxGNN score (0.9990) comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence. It is not independent clinical evidence.
An important caution applies. Triptans have historically carried cautionary labeling for basilar-type or brainstem aura because of theoretical concerns about vasoconstriction. No study in the data compiled for this report evaluates zolmitriptan specifically in brainstem aura, so safety must be reviewed before any recommendation.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
The publications below are the most relevant of those compiled. None specifically evaluates zolmitriptan in migraine with brainstem aura.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 25600718 | 2015 | Review | Headache | American Headache Society evidence assessment of drugs for acute migraine treatment in adults |
| 12083998 | 2002 | Review | Expert Opin Pharmacother | Randomised placebo-controlled trials show good 2-hour response and pain-free rates, with improvement in nausea, photophobia and phonophobia |
| 10473025 | 1999 | Review | Drugs | Oral zolmitriptan 2.5 and 5 mg has onset of action at about 45 minutes and is more effective than placebo |
| 25916333 | 2015 | Meta-analysis | J Headache Pain | Compared frovatriptan with rizatriptan, zolmitriptan and almotriptan in migraine with aura |
| 22644173 | 2012 | Subgroup analysis of RCT | Neurol Sci | Frovatriptan vs zolmitriptan 2.5 mg in a small subset of 18 patients with migraine with aura |
| 9399012 | 1997 | Preclinical | Cephalalgia | 5-HT1B/1D partial agonist that can inhibit trigeminovascular activation both centrally and peripherally |
| 12864759 | 2003 | Clinical study (mechanistic) | Headache | Transcranial Doppler in migraine attacks before and after oral zolmitriptan or sumatriptan |
| 17177580 | 2007 | Postmarketing surveillance | Clin Drug Investig | Effectiveness and satisfaction with zolmitriptan 5 mg nasal spray in real-life practice |
| 25538676 | 2014 | Review | Front Neurol | Treatment options in vestibular migraine, where dedicated trials are scarce |
| 22298171 | 2012 | Case report | Cardiol J | Case of zolmitriptan-induced acute myocardial infarction in a 45-year-old woman |
Canada Market Information
Zolmitriptan has 16 valid single-ingredient authorizations in Canada. The approved indication text and dosage forms are not available in the data compiled for this report. Product names suggest nasal spray and orally disintegrating formulations in addition to standard tablets.
| DIN | Product Name |
|---|---|
| 02238660 | ZOMIG |
| 02243045 | ZOMIG RAPIMELT |
| 02248992 | ZOMIG NASAL SPRAY |
| 02248993 | ZOMIG NASAL SPRAY |
| 02313960 | TEVA-ZOLMITRIPTAN |
The remaining 11 authorizations are generic products, including Sandoz, Teva (OD), Mint, Nat, NRA, Mar, Bio, Jamp and Auro versions.
Safety Considerations
- Contraindication-related conditions (from the knowledge graph, not label text): the drug-disease contraindication links include
- Cardiovascular and cerebrovascular conditions: coronary artery disease, myocardial infarction, myocardial ischemia, Prinzmetal angina, Wolff-Parkinson-White syndrome, stroke, transient ischemic attack, cerebral infarction, brain ischemia, intracranial arteriosclerosis, vertebrobasilar insufficiency, peripheral vascular disease, Raynaud disease
- Blood pressure: hypertension
- Organ disease: kidney disease, liver disease, gallbladder disease
- Other: ischemic bowel disease, hemoglobinopathy, familial or sporadic hemiplegic migraine
- Drug Interactions: 82 interactions were recorded. Those rated Major include lorcaserin, dolasetron, palonosetron, ondansetron, granisetron, dexfenfluramine, fenfluramine and sibutramine, which are mostly serotonergic agents. Moderate interactions include morphine, cimetidine and obeticholic acid.
- Case report: a published case describes acute myocardial infarction associated with zolmitriptan, consistent with the vasoconstriction concern for triptans.
The package insert warnings and contraindications were not available for this report, so please refer to the package insert for full safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The mechanistic link to migraine with brainstem aura is plausible, but there are no clinical trials and no publications that specifically evaluate zolmitriptan in this subtype. The high TxGNN score mainly reflects similarity to the approved migraine indication. Triptans have historically carried cautionary labeling for brainstem aura, and the knowledge graph lists many cerebrovascular contraindications. The other two predicted indications (atrophoderma vermiculata and ulerythema ophryogenesis) have no plausible mechanistic link, no trials and no literature, and should also stay on hold.
To proceed, the following is needed:
- Health Canada package insert warnings and contraindications, especially for basilar-type or brainstem aura (this is a blocking gap for safety screening)
- Detailed mechanism of action data from DrugBank
- A focused literature review and safety assessment for triptan use in brainstem aura, including vasoconstriction and stroke risk
- Approved indication text and dosage forms for the Canadian products
- If the safety review is acceptable, a well-designed clinical study in this specific subtype
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.